ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study.

ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study.

Future Oncol. 2017 Apr 21;:

Authors: Moscetti L, Mentuccia L, Vici P, Quadrini S, Sperduti I, Pizzuti L, Fabbri MA, Vaccaro A, Saccà MM, Barba M, Sergi D, Zampa G, Gamucci T

Abstract
AIM: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations.
PATIENTS & METHODS: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires.
RESULTS: A significant ESAS score improvement was observed with a 10% median decrease. No differences were revealed for the QoL scores.
CONCLUSION: The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.

PMID: 28429617 [PubMed - as supplied by publisher]

http://ift.tt/2p6bo1k